Cargando…
Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma
SIMPLE SUMMARY: The purpose of this retrospective study was to report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and PDAC. At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29....
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268077/ https://www.ncbi.nlm.nih.gov/pubmed/34206263 http://dx.doi.org/10.3390/cancers13133103 |
_version_ | 1783720277696315392 |
---|---|
author | Barat, Maxime Aldhaheri, Rauda Dohan, Anthony Fuks, David Kedra, Alice Hoeffel, Christine Oudjit, Ammar Coriat, Romain Barret, Maximilien Terris, Benoit Marchese, Ugo Soyer, Philippe |
author_facet | Barat, Maxime Aldhaheri, Rauda Dohan, Anthony Fuks, David Kedra, Alice Hoeffel, Christine Oudjit, Ammar Coriat, Romain Barret, Maximilien Terris, Benoit Marchese, Ugo Soyer, Philippe |
author_sort | Barat, Maxime |
collection | PubMed |
description | SIMPLE SUMMARY: The purpose of this retrospective study was to report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and PDAC. At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.51–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. A nomogram based on CT features identified at multivariable analysis yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. ABSTRACT: Purpose: To report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and pancreatic ductal adenocarcinoma (PDAC). Materials and methods: Thirty-four patients (24 men, 12 women; mean age, 63.3 ± 10.2 [SD] years) with CT and histopathologically proven PPM were analyzed by two independent readers and compared to 34 patients with PDAC. Diagnosis performances of each variable for the diagnosis of PPM against PDAC were calculated. Univariable and multivariable analyses were performed. A nomogram was developed to diagnose PPM against PDAC. Results: PPM mostly presented as single (34/34; 100%), enhancing (34/34; 100%), solid (27/34; 79%) pancreatic lesion without visible associated lymph nodes (24/34; 71%) and no Wirsung duct enlargement (29/34; 85%). At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.512–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. The nomogram yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. Conclusion: CT findings may help discriminate between PPM and PDAC. |
format | Online Article Text |
id | pubmed-8268077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82680772021-07-10 Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma Barat, Maxime Aldhaheri, Rauda Dohan, Anthony Fuks, David Kedra, Alice Hoeffel, Christine Oudjit, Ammar Coriat, Romain Barret, Maximilien Terris, Benoit Marchese, Ugo Soyer, Philippe Cancers (Basel) Article SIMPLE SUMMARY: The purpose of this retrospective study was to report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and PDAC. At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.51–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. A nomogram based on CT features identified at multivariable analysis yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. ABSTRACT: Purpose: To report the computed tomography (CT) features of pancreatic parenchymal metastasis (PPM) and identify CT features that may help discriminate between PPM and pancreatic ductal adenocarcinoma (PDAC). Materials and methods: Thirty-four patients (24 men, 12 women; mean age, 63.3 ± 10.2 [SD] years) with CT and histopathologically proven PPM were analyzed by two independent readers and compared to 34 patients with PDAC. Diagnosis performances of each variable for the diagnosis of PPM against PDAC were calculated. Univariable and multivariable analyses were performed. A nomogram was developed to diagnose PPM against PDAC. Results: PPM mostly presented as single (34/34; 100%), enhancing (34/34; 100%), solid (27/34; 79%) pancreatic lesion without visible associated lymph nodes (24/34; 71%) and no Wirsung duct enlargement (29/34; 85%). At multivariable analysis, well-defined margins (OR, 6.64; 95% CI: 1.47–29.93; p = 0.014), maximal enhancement during arterial phase (OR, 6.15; 95% CI: 1.13–33.51; p = 0.036), no vessel involvement (OR, 7.19; 95% CI: 1.512–34.14) and no Wirsung duct dilatation (OR, 10.63; 95% CI: 2.27–49.91) were independently associated with PPM. The nomogram yielded an AUC of 0.92 (95% CI: 0.85–0.98) for the diagnosis of PPM vs. PDAC. Conclusion: CT findings may help discriminate between PPM and PDAC. MDPI 2021-06-22 /pmc/articles/PMC8268077/ /pubmed/34206263 http://dx.doi.org/10.3390/cancers13133103 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Barat, Maxime Aldhaheri, Rauda Dohan, Anthony Fuks, David Kedra, Alice Hoeffel, Christine Oudjit, Ammar Coriat, Romain Barret, Maximilien Terris, Benoit Marchese, Ugo Soyer, Philippe Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma |
title | Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma |
title_full | Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma |
title_fullStr | Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma |
title_short | Utility of CT to Differentiate Pancreatic Parenchymal Metastasis from Pancreatic Ductal Adenocarcinoma |
title_sort | utility of ct to differentiate pancreatic parenchymal metastasis from pancreatic ductal adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268077/ https://www.ncbi.nlm.nih.gov/pubmed/34206263 http://dx.doi.org/10.3390/cancers13133103 |
work_keys_str_mv | AT baratmaxime utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT aldhaherirauda utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT dohananthony utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT fuksdavid utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT kedraalice utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT hoeffelchristine utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT oudjitammar utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT coriatromain utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT barretmaximilien utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT terrisbenoit utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT marcheseugo utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma AT soyerphilippe utilityofcttodifferentiatepancreaticparenchymalmetastasisfrompancreaticductaladenocarcinoma |